Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

A Feasibility Study of the ReLeaf Catheter System (ReLeaf)

26 mars 2018 mis à jour par: Intervene, Inc.

A Feasibility Study of the InterVene ReLeaf Catheter System in the Creation of Tissue Leaflets in the Femoral and/or Popliteal Vein

This study is designed to evaluate the safety and technical feasibility of the ReLeaf Catheter System in the creation of one or more tissue leaflets in the femoral and/or popliteal vein in subjects with chronic venous insufficiency and who meet the protocol entry criteria.

Aperçu de l'étude

Statut

Résilié

Intervention / Traitement

Description détaillée

The ReLeaf catheter system is intended for the creation of tissue leaflets in the deep veins where existing valve structures are no longer healthy and effectively moving blood.

This study aims to treat subjects with a documented history of symptomatic chronic venous insufficiency in whom compression therapy for at least 6 months, combined with superficial venous and/or perforator surgery have failed to obtain clinical improvement.

This clinical trial is designed to evaluate the safety and technical feasibility of the ReLeaf Catheter System in the creation of one or more tissue leaflets in the femoral and/or popliteal vein in subjects with chronic venous insufficiency and who meet the protocol entry criteria.

Type d'étude

Interventionnel

Inscription (Réel)

2

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • History of symptomatic chronic venous insufficiency subjects, clinical category CEAP 3 or greater.
  • History of failed compression therapy (of at least 6 months), combined with superficial venous or perforator surgery.
  • Femoral and/or popliteal venous reflux of ≥ 1.0 seconds.
  • Deep system reflux with Kistner classification grade 2 or higher.
  • 18 years of age or older at the time of consent.
  • Willing and able to sign the Ethics Committee (EC) approved informed consent form.
  • Willing to comply with follow-up evaluations and protocols.

Exclusion Criteria:

  • In the Investigator's opinion, venous outflow obstruction that would inhibit adequate flow away from valve site.
  • Obstructive features in the femoral or popliteal vein below the proposed tissue leaflet creation site, which, in the Investigator's opinion, will not allow for sufficient blood flow to the tissue leaflet creation site.
  • Deep venous system intervention within 6 months of consent.
  • Obstructive features or irregularly small luminal diameter in the femoral vein which, in the opinion of the Investigator, will prohibit access to a tissue leaflet creation site.
  • Prior deep vein valve surgical intervention in the ipsilateral limb.
  • Ankle arthrodesis with secondary muscle atrophy or severely limited ambulation.
  • Limb-threatening circulatory compromise.
  • Contraindications to anticoagulation therapy that cannot be medically controlled.
  • History of symptomatic pulmonary embolism.
  • Acute venous thromboembolism within 3 months of consent.
  • Comorbidity risks which, in the opinion of the Investigator, limit longevity or likelihood of complying with protocol follow up.
  • General contraindications to surgery or the use of anesthesia.
  • Uncontrolled heart failure, or NYHA Class III or IV heart failure.
  • Open Cardiac surgery (e.g. ventriculotomy, atriotomy) within the past 6 months of consent (Interventional procedures such as stenting or PTCA do not apply.)
  • Chronic Kidney Disease with creatinine level of 2mg/dL or higher.
  • Active systemic infection or sepsis.
  • Pregnant or lactating (positive pregnancy test, women of childbearing potential must be tested).
  • Appropriate vascular access is precluded.
  • Subject is enrolled in any other clinical study that, in the opinion of the Investigator, may conflict with this study or compromise study results.
  • Subject is considered at high risk for non-compliance with the protocol (e.g., inaccessible for follow-up).
  • Other invasive surgical procedure within the last 90 days that in the Investigator's opinion would interfere with the study procedure or results.
  • History of stroke within the last 6 months.
  • Subject is incarcerated or will be incarcerated during the course of the study.
  • Untreated significant superficial venous incompetence

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: N / A
  • Modèle interventionnel: Affectation à un seul groupe
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Treatment
Subject to undergo the ReLeaf study procedure.
The ReLeaf catheter is expected to enable a physician to create tissue leaflets that, in turn, generate a valve effect in the deep veins of the legs.
Autres noms:
  • Tissue Leaflet Creation, Creation of Valve-like Effect

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Technical Feasibility
Délai: Day 0
Technical feasibility will be evaluated as the ability of the ReLeaf Catheter System to access the target site and successfully modify tissue as confirmed by, and in the opinion of, the Investigator. Successful target site access and confirmed tissue modification will be used as a measure of technical feasibility.
Day 0
Safety (The number of SAEs directly attributable to the study device will be used as a measure of safety)
Délai: Day 30
Safety will be evaluated as freedom from serious adverse events directly attributed to the investigational device. The number of SAEs directly attributable to the study device will be used as a measure of safety.
Day 30

Autres mesures de résultats

Mesure des résultats
Description de la mesure
Délai
Efficacy
Délai: Day 365
Subsequent efficacy of the treatment following successful creation of the tissue leaflet(s). This will be measured through an assessment of tissue leaflet creation and the tissue leaflets ability to impact blood flow over the course of time.
Day 365
Durability
Délai: Day 365
Long-term durability of the tissue leaflet(s). Confirmation of tissue leaflet existence over time will be used to assess the durability of the tissue leaflet.
Day 365
Long-term Safety (Long-term safety will be measured by freedom from SAEs directly attributable to the study device)
Délai: Day 365
Further long-term safety data will be collected, analyzed and reported through the end of the study. Long-term safety will be measured by freedom from SAEs directly attributable to the study device.
Day 365

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

9 septembre 2015

Achèvement primaire (Réel)

8 octobre 2016

Achèvement de l'étude (Réel)

5 juin 2017

Dates d'inscription aux études

Première soumission

26 mai 2015

Première soumission répondant aux critères de contrôle qualité

2 juin 2015

Première publication (Estimation)

3 juin 2015

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

29 mars 2018

Dernière mise à jour soumise répondant aux critères de contrôle qualité

26 mars 2018

Dernière vérification

1 mars 2018

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • CLP-0001

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

Essais cliniques sur Insuffisance veineuse chronique

Essais cliniques sur ReLeaf

3
S'abonner